Skip to main content
Article thumbnail
Location of Repository

Optimal Management of Peripheral Arterial Disease for the Non-Specialist

By ME O'Donnell, JA Reid, LL Lau, RJ Hannon and B Lee


Peripheral arterial disease (PAD) now affects approximately 20% of adults older than 55 years to an estimated total of 27 million people in the Western World. The aim of this paper is to describe the medical management of PAD for the non-vascular specialist, particularly general practitioners, where PAD has now been included in the Northern Ireland Department of Health's Primary Care Service Framework (Directed Enhanced Service)

Topics: Grand Rounds
Publisher: The Ulster Medical Society
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences.
    2. Angioplasty (versus non surgical management) for intermittent claudication.
    3. Antithrombotic Trialist’s Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients.
    4. Assessment and management of foot disease in patients with diabetes.
    5. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study.
    6. Benefits of a supervised exercise program after lower limb bypass surgery. Vasc Endovascul Surg.
    7. (2011). Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. © The Ulster Medical Society,
    8. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
    9. (2001). Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev.
    10. Cilostazol for peripheral arterial disease.
    11. Cilostazol: a review of its use in intermittent claudication.
    12. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists.
    13. Comerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies.
    14. (1996). Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
    15. (2011). Consensus Document on chronic critical leg ischaemia. Eur J Vasc Surg. 1992;6 (Supp A): 1-32.© The Ulster Medical Society,
    16. Developing the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia.
    17. Diseasespecific quality of life assessment in intermittent claudication: review.
    18. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    19. Effect of cinnarizine on peripheral circulation in dogs.
    20. Effect of hyperhomocysteinemia on cardiovascular risk factors and initiation of atherosclerosis in Wistar rats.
    21. Effects of an angiotensin-converting-enzyyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study (HOPES) Investigators.
    22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
    23. Fialka V . A review of the clinical effectiveness of exercise therapy for intermittent claudication.
    24. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)--a review based on randomized, controlled studies.
    25. (2008). Health, Social Services and Public Safety, Northern Ireland. The primary medical services (direct enhanced services) directions
    26. Homocysteine lowering with folic acid and B vitamins in vascular disease.
    27. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study.
    28. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.
    29. Influence of smoking on incidence and prevalence of peripheral arterial disease.
    30. Intermittent claudication. A risk profile from The Framingham Heart Study.
    31. Interobserver variation in interpretation of arteriography and management of severe lower leg arterial disease.
    32. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images.
    33. Medical treatment of peripheral arterial disease.
    34. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
    35. Naftidrofuryl in intermittent claudication: a retrospective analysis.
    36. (1992). Percutaneous balloon angioplasty for arteriosclerosis obliterans: long term results. In:
    37. Peripheral arterial disease.
    38. (2004). Peripheral arterial disease. Clin Evid.
    39. Pharmacologic therapy for peripheral arterial disease and claudication.
    40. (2002). Pharmacologic treatment for intermittent claudication. Vasc Med.
    41. Physician advice for smoking cessation.
    42. (1999). Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Pract Diabetes Int.
    43. (1999). Predictors of early disease in the lower limbs. Semin Vasc Surg.
    44. (1999). Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey,
    45. (1997). Results of aortic bifurcation: a metaanalysis. J Vasc Surg.
    46. (2006). Scottish Collegiate Guidelines Network (SIGN) Diagnosis and Management of Peripheral Arterial Disease - A National Clinical Guideline.
    47. Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    48. (1985). The course of peripheral vascular disease in non-insulindependent diabetes. Diabetes Care.
    49. The effect of exercise on gait patterns in older women: a randomized controlled trial.
    50. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol.
    51. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance.
    52. The prognosis of non-critical limb ischaemia: a systematic review of population-based evidence.
    53. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vasc Endovascular Surg.
    54. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    55. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.
    56. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.
    57. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.
    58. Treatment of hypertension in peripheral arterial disease. Cochrane Database Systematic Reviews (Online)
    59. Use of a constitutively active hypoxia-inducible factor1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.